Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
On The Fly
Fly Intel: Wall Street's top stories for Wednesday » 16:18
07/08/20
07/08
16:18
07/08/20
16:18
LEVI

Levi Strauss

$12.68 /

-1.195 (-8.62%)

, FB

Facebook

$243.58 /

+2.51 (+1.04%)

, BIIB

Biogen

$280.15 /

+11.97 (+4.46%)

, ALL

Allstate

$88.20 /

-4.38 (-4.73%)

, NGHC

National General

$33.73 /

+13.29 (+65.02%)

, TWTR

Twitter

$35.39 /

+2.41 (+7.31%)

, MRNA

Moderna

$61.58 /

+0.5 (+0.82%)

, GM

General Motors

$24.93 /

-0.19 (-0.76%)

, FCAU

Fiat Chrysler

$9.99 /

-0.09 (-0.89%)

, XENT

Intersect ENT

$17.98 /

+4.07 (+29.26%)

, MDT

Medtronic

$91.64 /

-0.05 (-0.05%)

, NKLA

Nikola

$54.03 /

+13.78 (+34.24%)

, GILT

Gilat Satellite

$5.20 /

-0.905 (-14.82%)

, CMTL

Comtech

$15.87 /

+0.32 (+2.06%)

Stocks continue to rise…

Open Full Text

ShowHide Related Items >><<
XENT Intersect ENT
$17.98 /

+4.07 (+29.26%)

TWTR Twitter
$35.39 /

+2.41 (+7.31%)

NKLA Nikola
$54.03 /

+13.78 (+34.24%)

NGHC National General
$33.73 /

+13.29 (+65.02%)

MRNA Moderna
$61.58 /

+0.5 (+0.82%)

MDT Medtronic
$91.64 /

-0.05 (-0.05%)

LEVI Levi Strauss
$12.68 /

-1.195 (-8.62%)

GM General Motors
$24.93 /

-0.19 (-0.76%)

GILT Gilat Satellite
$5.20 /

-0.905 (-14.82%)

FCAU Fiat Chrysler
$9.99 /

-0.09 (-0.89%)

FB Facebook
$243.58 /

+2.51 (+1.04%)

CMTL Comtech
$15.87 /

+0.32 (+2.06%)

BIIB Biogen
$280.15 /

+11.97 (+4.46%)

ALL Allstate
$88.20 /

-4.38 (-4.73%)

LEVI Levi Strauss
$12.68 /

-1.195 (-8.62%)

06/16/20 Exane BNP Paribas
Levi Strauss initiated with an Outperform at Exane BNP Paribas
04/09/20 Guggenheim
Levi Strauss price target lowered to $16 from $26 at Guggenheim
04/08/20 Citi
Levi Strauss has ample liquidity and remains 'strong brand,' says Citi
03/18/20 BofA
Levi Strauss downgraded to Neutral with $15 price target at BofA
FB Facebook
$243.58 /

+2.51 (+1.04%)

07/07/20 BofA
Potential U.S. ban of TikTok could be tailwind to Snap engagement, says BofA
07/01/20 Monness Crespi
Facebook has opportunity to emerge from crisis stronger, says Monness Crespi
07/01/20 Goldman Sachs
Facebook checks show limited impact from ad boycott, says Goldman Sachs
06/30/20 Morgan Stanley
Morgan Stanley says buy Facebook amid boycott-driven weakness
BIIB Biogen
$280.15 /

+11.97 (+4.46%)

07/08/20 Credit Suisse
Biogen submits Aducanumab BLA, upside possible near-term, says Credit Suisse
07/08/20 Stifel
Biogen submission of Aducanumab BLA 'an incremental positive,' says Stifel
07/08/20 Goldman Sachs
Goldman says Biogen BLA submission for Alzheimer's drug an incremental positive
07/08/20 Jefferies
Biogen likely to get Priority Review for aducanumab, says Jefferies
ALL Allstate
$88.20 /

-4.38 (-4.73%)

07/08/20 William Blair
National General downgraded to Market Perform from Outperform at William Blair
07/08/20 B. Riley FBR
National General price target raised to $34.50 from $28 at B. Riley FBR
06/25/20
Fly Intel: Top five analyst upgrades
06/25/20 Credit Suisse
Allstate upgraded to Neutral from Underperform at Credit Suisse
NGHC National General
$33.73 /

+13.29 (+65.02%)

04/08/20
Fly Intel: Top five analyst initiations
04/08/20 JPMorgan
National General initiated with a Neutral at JPMorgan
TWTR Twitter
$35.39 /

+2.41 (+7.31%)

07/08/20 Rosenblatt
Rosenblatt says 'highly unlikely' Twitter considering paid subscription tiers
06/29/20 Stifel
Stifel says Facebook sales won't be materially hurt unless ad boycott broadens
06/29/20 JPMorgan
Facebook estimates not at risk from ad boycott, says JPMorgan
MRNA Moderna
$61.58 /

+0.5 (+0.82%)

07/08/20 Piper Sandler
Piper reiterates $100 target on Moderna after Phase II study enrolled
07/02/20 BMO Capital
Moderna mRNA platform supported by Pfizer vaccine data, says BMO Capital
06/30/20 Argus
Moderna initiated with a Buy at Argus
06/30/20 Argus
Moderna initiated with a Buy at Argus
GM General Motors
$24.93 /

-0.19 (-0.76%)

06/25/20 Morgan Stanley
Talks with Ford dealer highlight inventory risk, says Morgan Stanley
06/24/20 Morgan Stanley
GM electric vehicle business could be worth $100B, says Morgan Stanley
06/19/20 JPMorgan
General Motors price target raised to $33 from $29 at JPMorgan
06/18/20 Jefferies
Jefferies raises price targets for Ford, GM and FCA on balance sheet de-risking
FCAU Fiat Chrysler
$9.99 /

-0.09 (-0.89%)

06/30/20 UBS
Fiat Chrysler price target raised to EUR 9 from EUR 6 at UBS
06/22/20 Redburn
Fiat Chrysler upgraded to Buy from Neutral at Redburn
XENT Intersect ENT
$17.98 /

+4.07 (+29.26%)

07/08/20 Oppenheimer
Takeout bid of $17 for Intersect ENT would be 'reasonable,' says Oppenheimer
06/23/20 Oppenheimer
Intersect ENT initiated with a Perform at Oppenheimer
06/09/20 SVB Leerink
Intersect ENT C-code issuance has 'mixed implications,' says SVB Leerink
06/09/20 Piper Sandler
Intersect ENT's C-Code approval adds access to 40M lives, says Piper Sandler
MDT Medtronic
$91.64 /

-0.05 (-0.05%)

06/30/20 Stifel
Tandem Diabetes target raised to $80 after UnitedHealth coverage news at Stifel
06/30/20 Oppenheimer
UnitedHealth to start covering Tandem insulin pump, says Oppenheimer
06/30/20 Piper Sandler
United Health coverage a 'clear positive' for Tandem, says Piper Sandler
06/18/20 Argus
Medtronic has strong growth opportunities, says Argus
NKLA Nikola
$54.03 /

+13.78 (+34.24%)

07/08/20
Fly Intel: Top five analyst upgrades
07/08/20 JPMorgan
JPMorgan upgrades Nikola to Overweight after 40% July selloff
07/08/20 JPMorgan
Nikola upgraded to Overweight from Neutral at JPMorgan
07/07/20 RBC Capital
Nikola initiated with a Sector Perform at RBC Capital
GILT Gilat Satellite
$5.20 /

-0.905 (-14.82%)

CMTL Comtech
$15.87 /

+0.32 (+2.06%)

06/04/20 Northland
Comtech price target lowered to $24 from $27 at Northland
03/31/20 Citi
Comtech price target lowered to $17 from $34 at Citi
XENT Intersect ENT
$17.98 /

+4.07 (+29.26%)

TWTR Twitter
$35.39 /

+2.41 (+7.31%)

NGHC National General
$33.73 /

+13.29 (+65.02%)

MRNA Moderna
$61.58 /

+0.5 (+0.82%)

MDT Medtronic
$91.64 /

-0.05 (-0.05%)

LEVI Levi Strauss
$12.68 /

-1.195 (-8.62%)

GM General Motors
$24.93 /

-0.19 (-0.76%)

GILT Gilat Satellite
$5.20 /

-0.905 (-14.82%)

FCAU Fiat Chrysler
$9.99 /

-0.09 (-0.89%)

FB Facebook
$243.58 /

+2.51 (+1.04%)

CMTL Comtech
$15.87 /

+0.32 (+2.06%)

BIIB Biogen
$280.15 /

+11.97 (+4.46%)

ALL Allstate
$88.20 /

-4.38 (-4.73%)

  • 19
    May
  • 12
    Feb
XENT Intersect ENT
$17.98 /

+4.07 (+29.26%)

TWTR Twitter
$35.39 /

+2.41 (+7.31%)

NKLA Nikola
$54.03 /

+13.78 (+34.24%)

MRNA Moderna
$61.58 /

+0.5 (+0.82%)

MDT Medtronic
$91.64 /

-0.05 (-0.05%)

LEVI Levi Strauss
$12.68 /

-1.195 (-8.62%)

GM General Motors
$24.93 /

-0.19 (-0.76%)

GILT Gilat Satellite
$5.20 /

-0.905 (-14.82%)

FB Facebook
$243.58 /

+2.51 (+1.04%)

BIIB Biogen
$280.15 /

+11.97 (+4.46%)

XENT Intersect ENT
$17.98 /

+4.07 (+29.26%)

TWTR Twitter
$35.39 /

+2.41 (+7.31%)

NKLA Nikola
$54.03 /

+13.78 (+34.24%)

MRNA Moderna
$61.58 /

+0.5 (+0.82%)

MDT Medtronic
$91.64 /

-0.05 (-0.05%)

LEVI Levi Strauss
$12.68 /

-1.195 (-8.62%)

GM General Motors
$24.93 /

-0.19 (-0.76%)

FCAU Fiat Chrysler
$9.99 /

-0.09 (-0.89%)

FB Facebook
$243.58 /

+2.51 (+1.04%)

CMTL Comtech
$15.87 /

+0.32 (+2.06%)

BIIB Biogen
$280.15 /

+11.97 (+4.46%)

ALL Allstate
$88.20 /

-4.38 (-4.73%)

TWTR Twitter
$35.39 /

+2.41 (+7.31%)

NKLA Nikola
$54.03 /

+13.78 (+34.24%)

MRNA Moderna
$61.58 /

+0.5 (+0.82%)

MDT Medtronic
$91.64 /

-0.05 (-0.05%)

LEVI Levi Strauss
$12.68 /

-1.195 (-8.62%)

GM General Motors
$24.93 /

-0.19 (-0.76%)

FCAU Fiat Chrysler
$9.99 /

-0.09 (-0.89%)

FB Facebook
$243.58 /

+2.51 (+1.04%)

BIIB Biogen
$280.15 /

+11.97 (+4.46%)

Hot Stocks
Zymeworks announces new multispecific antibody collaboration with Merck » 16:16
07/08/20
07/08
16:16
07/08/20
16:16
ZYME

Zymeworks

$37.32 /

-1.34 (-3.47%)

, MRK

Merck

$77.87 /

-0.77 (-0.98%)

Zymeworks (ZYME)…

Zymeworks (ZYME) announced that it and longtime partner, Merck (MRK) have signed a new license agreement granting Merck the right to develop additional multispecific antibody therapeutic candidates using Zymeworks' Azymetric and EFECT platforms. Under the terms of the new research and license agreement, Zymeworks will provide Merck a worldwide, royalty-bearing license to research, develop and commercialize up to three new multispecific antibodies toward Merck's therapeutic targets. In exchange, Zymeworks will receive an undisclosed upfront payment and if each of the three programs yield an approved product, Zymeworks is eligible to receive up to $411M in option exercise fees and clinical development and regulatory approval milestone payments and up to $480M in commercial milestone payments, as well as tiered royalties on worldwide sales. Merck will also receive a worldwide, royalty-bearing license to research, develop and commercialize up to three multispecific antibodies in the animal health field in exchange for additional milestone payments and tiered royalties.

ShowHide Related Items >><<
ZYME Zymeworks
$37.32 /

-1.34 (-3.47%)

MRK Merck
$77.87 /

-0.77 (-0.98%)

ZYME Zymeworks
$37.32 /

-1.34 (-3.47%)

03/03/20 H.C. Wainwright
Zymeworks price target lowered to $60 from $65 at H.C. Wainwright
02/02/20 Stifel
Zymeworks price target raised to $70 from $45 at Stifel
01/15/20 Wells Fargo
Zymeworks price target raised to $58 from $48 at Wells Fargo
01/13/20 Guggenheim
Zymeworks named Best Idea at Guggenheim after Pfizer agreement
MRK Merck
$77.87 /

-0.77 (-0.98%)

06/30/20 SVB Leerink
Seattle Genetics price target raised to $167 from $155 at SVB Leerink
06/30/20 Oppenheimer
Seattle Genetics price target raised to $210 from $200 at Oppenheimer
06/25/20 Lake Street
Lake Street says Keytruda approval improves outlook for Checkpoint's cosibelimab
06/23/20 Maxim
Inovio price target raised to $24 from $18 at Maxim
ZYME Zymeworks
$37.32 /

-1.34 (-3.47%)

MRK Merck
$77.87 /

-0.77 (-0.98%)

  • 23
    Jan
MRK Merck
$77.87 /

-0.77 (-0.98%)

MRK Merck
$77.87 /

-0.77 (-0.98%)

MRK Merck
$77.87 /

-0.77 (-0.98%)

Recommendations
Opko Health price target raised to $6 from $4 at Piper Sandler » 13:08
07/08/20
07/08
13:08
07/08/20
13:08
OPK

Opko Health

$4.03 /

+0.2 (+5.22%)

, PFE

Pfizer

$33.72 /

-0.31 (-0.91%)

Piper Sandler analyst…

Piper Sandler analyst Edward Tenthoff raised the firm's price target on Opko Health (OPK) to $6 from $4 and reiterates an Overweight rating on the shares. The stock in afternoon trading is up 5% to $4.04. The analyst says "continued strong" SARS-CoV-2 PCR and growing antibody testing at BioReference Labs increases his confidence in the company's Service revenue forecast of $225M in Q2 and $896M this year. Further, partner Pfizer (PFE) will file in the Biologics License Application and Market Authorization Application for once-weekly somatrogon for treatment of growth hormone deficiency children this year, Tenthoff tells investors in a research note.

ShowHide Related Items >><<
PFE Pfizer
$33.72 /

-0.31 (-0.91%)

OPK Opko Health
$4.03 /

+0.2 (+5.22%)

OPK Opko Health
$4.03 /

+0.2 (+5.22%)

06/09/20 Piper Sandler
Opko Health price target raised to $4 from $3 at Piper Sandler
06/08/20 Piper Sandler
Opko Health, Pfizer data show IGF-1 normal at ENDO, says Piper Sandler
06/01/20 Piper Sandler
Piper keeps Overweight rating on Opko Health as FDA clears COVID-19 trial start
04/29/20 Piper Sandler
Piper backs Overweight on Opko as BioReference starts COVID-19 antibody testing
PFE Pfizer
$33.72 /

-0.31 (-0.91%)

07/08/20 Argus
Pfizer positioned for stronger revenue growth in 2021 and beyond, says Argus
07/07/20 Needham
Vaxcyte initiated with a Buy at Needham
07/02/20 B. Riley FBR
Novavax should be bought on weakness from Pfizer data, says B. Riley FBR
07/02/20 BMO Capital
Moderna mRNA platform supported by Pfizer vaccine data, says BMO Capital
PFE Pfizer
$33.72 /

-0.31 (-0.91%)

OPK Opko Health
$4.03 /

+0.2 (+5.22%)

  • 25
    Oct
PFE Pfizer
$33.72 /

-0.31 (-0.91%)

OPK Opko Health
$4.03 /

+0.2 (+5.22%)

PFE Pfizer
$33.72 /

-0.31 (-0.91%)

OPK Opko Health
$4.03 /

+0.2 (+5.22%)

PFE Pfizer
$33.72 /

-0.31 (-0.91%)

OPK Opko Health
$4.03 /

+0.2 (+5.22%)

Periodicals
J&J's Cilag to offer up to 11.8M Idorsia ordinary shares, Reuters says » 12:18
07/08/20
07/08
12:18
07/08/20
12:18
JNJ

Johnson & Johnson

$142.24 /

-0.57 (-0.40%)

, IDRSF

Idorsia

$0.00 /

+ (+0.00%)

, GS

Goldman Sachs

$200.28 /

+1.02 (+0.51%)

Johnson &…

Johnson & Johnson's (JNJ) Cilag Holding intends to offer up to roughly 11.8M existing ordinary shares in Idorsia (IDRSF) in an accelerated bookbuilding to begin on Wednesday, Reuters' Brenna Hughes Neghaiwi reports, citing the transaction's bookrunner. The sale corresponds to about 8.3% of Idorsia's outstanding ordinary share capital, the author says, noting that Goldman Sachs (GS) will serve as sole bookrunner. Reference Link

ShowHide Related Items >><<
JNJ Johnson & Johnson
$142.24 /

-0.57 (-0.40%)

GS Goldman Sachs
$200.28 /

+1.02 (+0.51%)

JNJ Johnson & Johnson
$142.24 /

-0.57 (-0.40%)

07/06/20 Baird
Cooper Companies downgraded to Neutral, Baird see confluence of issues
07/01/20 JMP Securities
Minerva's seltorexant still 'underappreciated' upside driver, says JMP
06/23/20 Maxim
Inovio price target raised to $24 from $18 at Maxim
05/29/20 H.C. Wainwright
H.C. Wainwright sees path forward for Minerva's roluperidone despite setback
IDRSF Idorsia
$0.00 /

+ (+0.00%)

07/08/20 JPMorgan
Idorsia initiated with a Neutral at JPMorgan
06/15/20 Deutsche Bank
Idorsia initiated with a Buy at Deutsche Bank
05/11/20 Credit Suisse
Idorsia upgraded to Outperform from Neutral at Credit Suisse
04/20/20 H.C. Wainwright
Idorsia price target raised to CHF 45 from CHF 38 at H.C. Wainwright
GS Goldman Sachs
$200.28 /

+1.02 (+0.51%)

07/08/20 Seaport Global
Goldman Sachs initiated with a Buy at Seaport Global
06/26/20 Morgan Stanley
Morgan Stanley sees dividend cuts at Wells Fargo, Capital One after stress tests
06/05/20 Wells Fargo
Goldman Sachs price target raised to $255 from $230 at Wells Fargo
06/04/20
Fly Intel: Top five analyst downgrades
JNJ Johnson & Johnson
$142.24 /

-0.57 (-0.40%)

GS Goldman Sachs
$200.28 /

+1.02 (+0.51%)

JNJ Johnson & Johnson
$142.24 /

-0.57 (-0.40%)

GS Goldman Sachs
$200.28 /

+1.02 (+0.51%)

JNJ Johnson & Johnson
$142.24 /

-0.57 (-0.40%)

GS Goldman Sachs
$200.28 /

+1.02 (+0.51%)

JNJ Johnson & Johnson
$142.24 /

-0.57 (-0.40%)

GS Goldman Sachs
$200.28 /

+1.02 (+0.51%)

Options
AstraZeneca call volume above normal and directionally bullish » 12:05
07/08/20
07/08
12:05
07/08/20
12:05
AZN

AstraZeneca

$54.51 /

+1.02 (+1.91%)

Bullish option flow…

Bullish option flow detected in AstraZeneca with 25,072 calls trading, 1.9x expected, and implied vol increasing over 1 point to 40.97%. 7/10 weekly 54.5 calls and Jul-20 55 calls are the most active options, with total volume in those strikes near 17,200 contracts. The Put/Call Ratio is 0.02. Earnings are expected on July 30th.

ShowHide Related Items >><<
AZN AstraZeneca
$54.51 /

+1.02 (+1.91%)

AZN AstraZeneca
$54.51 /

+1.02 (+1.91%)

06/24/20 Oddo BHF
AstraZeneca downgraded to Reduce from Buy at Oddo BHF
06/23/20 Maxim
Inovio price target raised to $24 from $18 at Maxim
06/10/20 Cowen
AstraZeneca price target raised to $60 from $55 at Cowen
06/10/20 Guggenheim
Merck's bladder cancer failure boosts strategic value of Padcev, says Guggenheim
AZN AstraZeneca
$54.51 /

+1.02 (+1.91%)

AZN AstraZeneca
$54.51 /

+1.02 (+1.91%)

AZN AstraZeneca
$54.51 /

+1.02 (+1.91%)

AZN AstraZeneca
$54.51 /

+1.02 (+1.91%)

Recommendations
Piper reiterates $100 target on Moderna after Phase II study enrolled » 11:38
07/08/20
07/08
11:38
07/08/20
11:38
MRNA

Moderna

$59.65 /

-1.43 (-2.34%)

Piper Sandler analyst…

Piper Sandler analyst Edward Tenthoff reiterates an Overweight rating on Moderna with a $100 price target after the company completed enrollment of 600 subjects in the Phase II study of SARS-CoV-2 vaccine mRNA-1273. The stock in midday trading is down $1.03 to $60.06. Separately, the National Institutes of Health has also completed enrollment of the older adult cohorts with results expected to be published soon, the analyst adds. In addition, Tenthoff finds it important that the National Institute of Allergy and Infectious Diseases/NIH partnered Phase III protocol has been finalized based on FDA feedback and is on-track to begin in July.

ShowHide Related Items >><<
MRNA Moderna
$59.65 /

-1.43 (-2.34%)

MRNA Moderna
$59.65 /

-1.43 (-2.34%)

07/02/20 BMO Capital
Moderna mRNA platform supported by Pfizer vaccine data, says BMO Capital
06/30/20 Argus
Moderna initiated with a Buy at Argus
06/30/20 Argus
Moderna initiated with a Buy at Argus
06/26/20 Morgan Stanley
Morgan Stanley says Axios overstates contention on Moderna-NIH vaccine ownership
MRNA Moderna
$59.65 /

-1.43 (-2.34%)

  • 19
    May
  • 12
    Feb
MRNA Moderna
$59.65 /

-1.43 (-2.34%)

MRNA Moderna
$59.65 /

-1.43 (-2.34%)

MRNA Moderna
$59.65 /

-1.43 (-2.34%)

Downgrade
Fly Intel: Top five analyst downgrades » 10:05
07/08/20
07/08
10:05
07/08/20
10:05
MO

Altria Group

$40.42 /

+0.47 (+1.18%)

, VSTO

Vista Outdoor

$15.20 /

-0.07 (-0.46%)

, HUBS

HubSpot

$232.50 /

-2.535 (-1.08%)

, BAH

Booz Allen

$75.00 /

-0.45 (-0.60%)

, CACI

CACI

$202.99 /

-1.97 (-0.96%)

, NVAX

Novavax

$100.31 /

-4.25 (-4.06%)

Catch up on today's…

Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Altria Group (MO) downgraded to Equal Weight from Overweight at Barclays with analyst Gaurav Jain saying the company is 100% U.S.-exposed and continues to lose market share. 2. Vista Outdoor (VSTO) downgraded to Neutral from Buy at B. Riley FBR with analyst Eric Wold saying the shares have increased by 115% over the past two months. 3. HubSpot (HUBS) downgraded to Neutral from Buy at Mizuho with analyst Siti Panigrahi saying the company has responded to small- and mid-sized businesses being hit hard by COVID-19 with discounts, downgrades, and large promotions. 4. Booz Allen (BAH) and CACI (CACI) were downgraded to Market Perform from Outperform at Raymond James. 5. Novavax (NVAX) downgraded to Neutral from Buy at Ladenburg with analyst Michael Higgins citing valuation. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

ShowHide Related Items >><<
VSTO Vista Outdoor
$15.20 /

-0.07 (-0.46%)

NVAX Novavax
$100.31 /

-4.25 (-4.06%)

MO Altria Group
$40.42 /

+0.47 (+1.18%)

CACI CACI
$202.99 /

-1.97 (-0.96%)

BAH Booz Allen
$75.00 /

-0.45 (-0.60%)

MO Altria Group
$40.42 /

+0.47 (+1.18%)

07/08/20 Barclays
Altria downgraded to Equal Weight on share losses at Barclays
07/08/20 Barclays
Altria Group downgraded to Equal Weight from Overweight at Barclays
07/07/20 Stifel
IQOS reduced exposure claim a 'win' for Philip Morris, Altria, says Stifel
04/20/20 Deutsche Bank
Altria Group price target lowered to $51 from $56 at Deutsche Bank
VSTO Vista Outdoor
$15.20 /

-0.07 (-0.46%)

07/08/20 B. Riley FBR
Vista Outdoor downgraded to Neutral after 115% rally at B. Riley FBR
07/08/20 B. Riley FBR
Vista Outdoor downgraded to Neutral from Buy at B. Riley FBR
07/07/20 Lake Street
Vista Outdoor price target raised to $18 from $13 at Lake Street
06/25/20 Monness Crespi
Vista Outdoor price target raised to $15 from $12 at Monness Crespi
HUBS HubSpot
$232.50 /

-2.535 (-1.08%)

07/08/20 Mizuho
HubSpot downgraded to Neutral on near-term headwinds at Mizuho
07/08/20 Mizuho
HubSpot downgraded to Neutral from Buy at Mizuho
06/29/20 Goldman Sachs
HubSpot price target raised to $263 from $184 at Goldman Sachs
05/07/20 Raymond James
HubSpot price target raised to $190 from $175 at Raymond James
BAH Booz Allen
$75.00 /

-0.45 (-0.60%)

07/08/20 Raymond James
Booz Allen downgraded to Market Perform from Outperform at Raymond James
07/08/20 Raymond James
Booz Allen downgraded to Market Perform from Outperform at Raymond James
06/29/20 William Blair
William Blair says Booz Allen looks to have renewed 2020's biggest expiring deal
06/05/20 William Blair
William Blair back Outperform on Booz Allen after USAF research lab task order
CACI CACI
$202.99 /

-1.97 (-0.96%)

07/08/20 Raymond James
CACI downgraded to Market Perform from Outperform at Raymond James
07/08/20 Raymond James
CACI downgraded to Market Perform from Outperform at Raymond James
06/12/20 William Blair
William Blair sees near-term takeover of Perspecta as unlikely despite Jana news
05/04/20 Wells Fargo
Leidos price target raised to $114 from $105 at Wells Fargo
NVAX Novavax
$100.31 /

-4.25 (-4.06%)

07/08/20 Ladenburg
Novavax downgraded to Neutral from Buy at Ladenburg
07/07/20 Cantor Fitzgerald
Novavax price target raised to $148 from $88 at Cantor Fitzgerald
07/02/20 B. Riley FBR
Novavax should be bought on weakness from Pfizer data, says B. Riley FBR
06/29/20 B. Riley FBR
Novavax price target raised to $106 from $74 at B. Riley FBR
VSTO Vista Outdoor
$15.20 /

-0.07 (-0.46%)

NVAX Novavax
$100.31 /

-4.25 (-4.06%)

MO Altria Group
$40.42 /

+0.47 (+1.18%)

HUBS HubSpot
$232.50 /

-2.535 (-1.08%)

CACI CACI
$202.99 /

-1.97 (-0.96%)

BAH Booz Allen
$75.00 /

-0.45 (-0.60%)

VSTO Vista Outdoor
$15.20 /

-0.07 (-0.46%)

NVAX Novavax
$100.31 /

-4.25 (-4.06%)

MO Altria Group
$40.42 /

+0.47 (+1.18%)

CACI CACI
$202.99 /

-1.97 (-0.96%)

VSTO Vista Outdoor
$15.20 /

-0.07 (-0.46%)

NVAX Novavax
$100.31 /

-4.25 (-4.06%)

MO Altria Group
$40.42 /

+0.47 (+1.18%)

HUBS HubSpot
$232.50 /

-2.535 (-1.08%)

CACI CACI
$202.99 /

-1.97 (-0.96%)

BAH Booz Allen
$75.00 /

-0.45 (-0.60%)

NVAX Novavax
$100.31 /

-4.25 (-4.06%)

MO Altria Group
$40.42 /

+0.47 (+1.18%)

Hot Stocks
Moderna says COVID-19 Phase 3 study protocol finalized with FDA » 09:48
07/08/20
07/08
09:48
07/08/20
09:48
MRNA

Moderna

$60.88 /

-0.2 (-0.33%)

, CTLT

Catalent

$74.13 /

+0.43 (+0.58%)

Moderna said it has…

Moderna said it has finalized the Phase 3 study protocol based on feedback from the U.S. Food and Drug Administration. "The randomized, 1:1 placebo-controlled trial is expected to include approximately 30,000 participants at the 100 microgram dose level in the U.S. and is expected to be conducted in collaboration with NIAID, subject to regulatory approval. Moderna has completed manufacture of vaccine required to start the Phase 3 study. With the Phase 3 dose at 100 undefined, the Company remains on track to be able to deliver approximately 500 million doses per year, and possibly up to 1 billion doses per year, beginning in 2021 from the company's internal U.S. manufacturing site and strategic collaboration with Lonza. In addition, Moderna recently announced a collaboration with Catalent for large-scale, commercial fill-finish manufacturing of mRNA-1273 at Catalent's biologics facility in Indiana," Moderna stated.

ShowHide Related Items >><<
MRNA Moderna
$60.88 /

-0.2 (-0.33%)

CTLT Catalent
$74.13 /

+0.43 (+0.58%)

MRNA Moderna
$60.88 /

-0.2 (-0.33%)

07/02/20 BMO Capital
Moderna mRNA platform supported by Pfizer vaccine data, says BMO Capital
06/30/20 Argus
Moderna initiated with a Buy at Argus
06/30/20 Argus
Moderna initiated with a Buy at Argus
06/26/20 Morgan Stanley
Morgan Stanley says Axios overstates contention on Moderna-NIH vaccine ownership
CTLT Catalent
$74.13 /

+0.43 (+0.58%)

06/26/20 Baird
Catalent price target raised to $80 from $74 at Baird
06/25/20 Argus
Catalent initiated with a Buy at Argus
05/06/20 Baird
Catalent price target raised to $74 from $63 at Baird
04/29/20 Stephens
Catalent deal with J&J could represent $600M revenue opportunity, says Stephens
MRNA Moderna
$60.88 /

-0.2 (-0.33%)

CTLT Catalent
$74.13 /

+0.43 (+0.58%)

  • 11
    Jun
  • 19
    May
  • 12
    Feb
  • 04
    Feb
MRNA Moderna
$60.88 /

-0.2 (-0.33%)

CTLT Catalent
$74.13 /

+0.43 (+0.58%)

MRNA Moderna
$60.88 /

-0.2 (-0.33%)

CTLT Catalent
$74.13 /

+0.43 (+0.58%)

MRNA Moderna
$60.88 /

-0.2 (-0.33%)

Hot Stocks
Moderna completes enrollment of Phase 2 study of COVID-19 mRNA vaccine » 09:47
07/08/20
07/08
09:47
07/08/20
09:47
MRNA

Moderna

$60.27 /

-0.81 (-1.33%)

Moderna announced that it…

Moderna announced that it has completed enrollment for both cohorts of the Phase 2 study of its vaccine candidate, mRNA-1273, against COVID-19. mRNA-1273 is Moderna's second mRNA vaccine for an infectious disease to complete enrollment of a Phase 2 study, following the company's CMV Phase 2 study, which was fully enrolled on March 3, the company stated. On June 11, "13 days after the first participant was dosed," the company announced that the cohort of healthy younger adults ages 18-55 and the sentinel group of older adults ages 55 years and above in the Phase 2 study of mRNA-1273 was complete. The company also announced that the cohorts of older adults and elderly adults in NIH-led Phase 1 study have completed enrollment. Results are expected to be published once available.

ShowHide Related Items >><<
MRNA Moderna
$60.27 /

-0.81 (-1.33%)

MRNA Moderna
$60.27 /

-0.81 (-1.33%)

07/02/20 BMO Capital
Moderna mRNA platform supported by Pfizer vaccine data, says BMO Capital
06/30/20 Argus
Moderna initiated with a Buy at Argus
06/30/20 Argus
Moderna initiated with a Buy at Argus
06/26/20 Morgan Stanley
Morgan Stanley says Axios overstates contention on Moderna-NIH vaccine ownership
MRNA Moderna
$60.27 /

-0.81 (-1.33%)

  • 19
    May
  • 12
    Feb
MRNA Moderna
$60.27 /

-0.81 (-1.33%)

MRNA Moderna
$60.27 /

-0.81 (-1.33%)

MRNA Moderna
$60.27 /

-0.81 (-1.33%)

Options
Unusually active option classes on open July 8th » 09:40
07/08/20
07/08
09:40
07/08/20
09:40
WMT

Walmart

$126.97 /

+ (+0.00%)

, BIIB

Biogen

$268.18 /

+ (+0.00%)

, TME

Tencent Music

$16.41 /

+ (+0.00%)

, AG

First Majestic

$9.68 /

+ (+0.00%)

, NEM

Newmont

$62.45 /

+ (+0.00%)

, SLV

iShares Silver Trust

$17.01 /

+0.01 (+0.06%)

, SE

Sea Limited

$112.74 /

+ (+0.00%)

, WBA

Walgreens Boots Alliance

$42.23 /

+ (+0.00%)

, GOLD

Barrick Gold

$27.01 /

+ (+0.00%)

, NVAX

Novavax

$104.56 /

+ (+0.00%)

Unusual total active…

Unusual total active option classes on open include: Wal-Mart (WMT), Biogen (BIIB), Tencent (TME), First Majestic Silver (AG), Newmont Mining (NEM), iShares Silver Trust (SLV), Sea Limited (SE), Walgreen Boots (WBA), Barrick Gold (GOLD), and Novavax (NVAX).

ShowHide Related Items >><<
WMT Walmart
$126.97 /

+ (+0.00%)

WBA Walgreens Boots Alliance
$42.23 /

+ (+0.00%)

TME Tencent Music
$16.41 /

+ (+0.00%)

SE Sea Limited
$112.74 /

+ (+0.00%)

NVAX Novavax
$104.56 /

+ (+0.00%)

NEM Newmont
$62.45 /

+ (+0.00%)

GOLD Barrick Gold
$27.01 /

+ (+0.00%)

BIIB Biogen
$268.18 /

+ (+0.00%)

AG First Majestic
$9.68 /

+ (+0.00%)

WMT Walmart
$126.97 /

+ (+0.00%)

07/08/20 Morgan Stanley
Walmart membership plan seems geared at protecting grocery, says Morgan Stanley
07/08/20 Oppenheimer
Walmart moving in on Amazon turf with new subscription service, says Oppenheimer
07/08/20 Baird
Walmart poised to lead in Digital Grocery, says Baird
07/08/20 Deutsche Bank
Walmart subscription business a 'big plus,' says Deutsche Bank
BIIB Biogen
$268.18 /

+ (+0.00%)

07/08/20 Credit Suisse
Biogen submits Aducanumab BLA, upside possible near-term, says Credit Suisse
07/08/20 Stifel
Biogen submission of Aducanumab BLA 'an incremental positive,' says Stifel
07/08/20 Goldman Sachs
Goldman says Biogen BLA submission for Alzheimer's drug an incremental positive
07/08/20 Jefferies
Biogen likely to get Priority Review for aducanumab, says Jefferies
TME Tencent Music
$16.41 /

+ (+0.00%)

06/30/20 UBS
Tencent Music upgraded to Buy from Neutral at UBS
06/30/20 Citi
Tencent Music initiated with a Buy at Citi
03/18/20 BOCOM
Tencent Music upgraded to Neutral from Sell at BOCOM
03/12/20 Morgan Stanley
Tencent Music upgraded to Overweight from Equal Weight at Morgan Stanley
AG First Majestic
$9.68 /

+ (+0.00%)

05/21/20 National Bank
First Majestic price target raised to C$16 from C$12.50 at National Bank
05/15/20 B. Riley FBR
First Majestic price target lowered to $6.75 from $7.80 at B. Riley FBR
04/06/20 Cormark
First Majestic downgraded to Market Perform from Buy at Cormark
NEM Newmont
$62.45 /

+ (+0.00%)

06/29/20 Citi
Newmont price target lowered to $70 from $74 at Citi
05/18/20 Standpoint Research
Newmont downgraded to Hold from Buy at Standpoint Research
05/06/20 Deutsche Bank
Newmont price target raised to $70 from $54 at Deutsche Bank
05/06/20 Citi
Newmont price target raised to $70 from $46 at Citi
SLV iShares Silver Trust
$17.01 /

+0.01 (+0.06%)

SE Sea Limited
$112.74 /

+ (+0.00%)

07/08/20 Citi
Sea Limited price target raised to $138 from $79 at Citi
06/30/20 Stephens
Sea Limited initiated with an Overweight at Stephens
06/30/20 Stephens
Sea Limited initiated with an Overweight at Stephens
05/19/20 CLSA
Sea Limited upgraded to Outperform from Underperform at CLSA
WBA Walgreens Boots Alliance
$42.23 /

+ (+0.00%)

07/02/20 Morgan Stanley
Morgan Stanley lowers Walgreens price target to $45 ahead of earnings
06/29/20 Lake Street
Option Care Health should be bought on S-3 filing dip, says Lake Street
06/04/20 Mizuho
Walgreens Boots Alliance price target lowered to $48 from $53 at Mizuho
05/19/20 Cowen
Walgreens Boots Alliance price target lowered to $48 from $54 at Cowen
GOLD Barrick Gold
$27.01 /

+ (+0.00%)

06/29/20 Citi
Barrick Gold price target raised to $27 from $19 at Citi
05/07/20 Deutsche Bank
Barrick Gold price target raised to $34 from $25 at Deutsche Bank
04/16/20 Barclays
Barrick Gold downgraded to Equal Weight from Overweight at Barclays
04/01/20 TD Securities
Barrick Gold upgraded to Action List Buy from Hold at TD Securities
NVAX Novavax
$104.56 /

+ (+0.00%)

07/08/20 Ladenburg
Novavax downgraded to Neutral from Buy at Ladenburg
07/07/20 Cantor Fitzgerald
Novavax price target raised to $148 from $88 at Cantor Fitzgerald
07/02/20 B. Riley FBR
Novavax should be bought on weakness from Pfizer data, says B. Riley FBR
06/29/20 B. Riley FBR
Novavax price target raised to $106 from $74 at B. Riley FBR
WMT Walmart
$126.97 /

+ (+0.00%)

WBA Walgreens Boots Alliance
$42.23 /

+ (+0.00%)

TME Tencent Music
$16.41 /

+ (+0.00%)

SE Sea Limited
$112.74 /

+ (+0.00%)

NVAX Novavax
$104.56 /

+ (+0.00%)

NEM Newmont
$62.45 /

+ (+0.00%)

GOLD Barrick Gold
$27.01 /

+ (+0.00%)

BIIB Biogen
$268.18 /

+ (+0.00%)

AG First Majestic
$9.68 /

+ (+0.00%)

WMT Walmart
$126.97 /

+ (+0.00%)

WBA Walgreens Boots Alliance
$42.23 /

+ (+0.00%)

TME Tencent Music
$16.41 /

+ (+0.00%)

NVAX Novavax
$104.56 /

+ (+0.00%)

NEM Newmont
$62.45 /

+ (+0.00%)

GOLD Barrick Gold
$27.01 /

+ (+0.00%)

BIIB Biogen
$268.18 /

+ (+0.00%)

AG First Majestic
$9.68 /

+ (+0.00%)

WMT Walmart
$126.97 /

+ (+0.00%)

WBA Walgreens Boots Alliance
$42.23 /

+ (+0.00%)

TME Tencent Music
$16.41 /

+ (+0.00%)

SE Sea Limited
$112.74 /

+ (+0.00%)

NVAX Novavax
$104.56 /

+ (+0.00%)

BIIB Biogen
$268.18 /

+ (+0.00%)

WMT Walmart
$126.97 /

+ (+0.00%)

WBA Walgreens Boots Alliance
$42.23 /

+ (+0.00%)

TME Tencent Music
$16.41 /

+ (+0.00%)

SLV iShares Silver Trust
$17.01 /

+0.01 (+0.06%)

SE Sea Limited
$112.74 /

+ (+0.00%)

NVAX Novavax
$104.56 /

+ (+0.00%)

NEM Newmont
$62.45 /

+ (+0.00%)

GOLD Barrick Gold
$27.01 /

+ (+0.00%)

BIIB Biogen
$268.18 /

+ (+0.00%)

AG First Majestic
$9.68 /

+ (+0.00%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.